Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 9/20 | 0.56 |
| ▸ | GSK3B | P49841 | 7/20 | 0.56 |
| ▸ | CDK9 | P50750 | 4/20 | 0.54 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.54 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.54 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.54 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.54 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.54 |
| ▸ | AURKA | O14965 | 3/20 | 0.52 |
| ▸ | RET | P07949 | 2/20 | 0.52 |
| ▸ | CDK4 | P11802 | 1/20 | 0.52 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.51 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.51 |
| ▸ | CLK1 | P49759 | 1/20 | 0.51 |
| ▸ | CLK2 | P49760 | 1/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.51 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.49 |
| ▸ | CDK1 | P06493 | 2/20 | 0.49 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.49 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13357718 | 0.87 | CDK9 (0.57) | CDK2GSK3BCDK9CDK5CCNT1 | |
| SCHEMBL3251377 | 0.85 | CDK2 (0.57) | CDK2GSK3BCDK9CDK5CCNT1 | |
| SCHEMBL3251529 | 0.85 | CDK9 (0.57) | CDK2GSK3BCDK9CDK5CCNT1 | |
| SCHEMBL13357713 | 0.84 | CDK9 (0.65) | CDK2GSK3BCDK9CDK5CCNT1 | |
| SCHEMBL15533895 | 0.81 | GSK3B (0.58) | CDK2GSK3BCDK9CDK5AURKA | |
| SCHEMBL15534241 | 0.81 | CLK1 (0.63) | CDK2GSK3BCDK5AURKACDK4 | |
| SCHEMBL12274955 | 0.76 | ABL1 (0.56) | CDK2GSK3BCDK5CCNA2CCNA1 | |
| SCHEMBL5203806 | 0.76 | CDK2 (0.65) | CDK2GSK3BAURKACDK4CLK4 | |
| SCHEMBL30847342 | 0.76 | ABL1 (0.57) | CDK2GSK3BCDK9CCNT1CCNA2 | |
| SCHEMBL27109944 | 0.76 | ABL1 (0.57) | CDK2GSK3BCDK9CCNT1CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1896470-B1 | PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-05-26 | — | — | EP | claimed |
| US-20080300267-A1 | Compounds and Compositions as Protein Kinase Inhibitors | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2008-12-04 | — | — | US | claimed |
| EP-1896470-A2 | PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2008-03-12 | — | — | EP | claimed |
| WO-2006124863-A2 | PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-11-23 | — | — | WO | claimed |
| EP-1896470-B1 | PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-05-26 | — | — | EP | disclosed |
| EP-1896470-B1 | PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-05-26 | — | — | EP | disclosed |
| US-20080300267-A1 | Compounds and Compositions as Protein Kinase Inhibitors | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2008-12-04 | — | — | US | disclosed |
| US-20080300267-A1 | Compounds and Compositions as Protein Kinase Inhibitors | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2008-12-04 | — | — | US | disclosed |
| US-20080300267-A1 | Compounds and Compositions as Protein Kinase Inhibitors | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2008-12-04 | — | — | US | disclosed |
| EP-1896470-A2 | PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006124863-A2 | PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300267-A1 | Compounds and Compositions as Protein Kinase Inhibitors | ERBB2, JAK2, AURKC | CDK2 9/4885GSK3B 164/4885CDK9 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.